anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Protease conjugates such as subtilisin conjugates are provided comprising a protease moiety and one or more addition moieties wherein the protease moiety has a modified amino acid sequence of a parent amino acid sequence. The parent amino acid sequence comprises a first epitope region, a second epitope region and a third epitope region, and the modified amino acid sequence comprises a substitution by a substituting amino acid at one or more positions in one or more of the epitope regions. When a substitution occurs in the first epitope region, the substitution occurs at one or more positions corresponding to positions 70-84 of subtilisin BPN'. When a substitution occurs in the second epitope region, the substitution occurs at one or more positions corresponding to positions 103-126 of subtilisin BPN'. When a substitution occurs in the third epitope region, the substitution occurs at one or more positions corresponding to positions 217-252 of subtilisin BPN'. Each addition moiety is covalently attached to one of the substituting amino acids. Cleaning and personal care compositions are provided containing the protease conjugates which have reduced immunogenicity relative to their corresponding parent proteases.
The participants for control clusters will be (the infant who has completed his/her 6 month of age from the date of birth along with their mother) will be enrolled from MNCH database according to criteria. The mother-infant pairs from control cluster will receive the usual care.
INTRODUCTION: Patients in the community with suspected Chronic limb-threatening ischaemia (CLTI) should be urgently referred to vascular services for investigation and management. The Theoretical Domains Framework (TDF) allows identification of influences on health professional behaviour in order to inform future interventions. Here, the TDF is used to explore primary care clinicians' behaviours with regards to recognition and referral of CLTI.
METHODS: Semi-structured interviews were conducted with 20 podiatrists, nurses and general practitioners in primary care. Directed content analysis was performed according to the framework method. Utterances were coded to TDF domains, and belief statements were defined by grouping similar utterances. Relevance of domains was confirmed according to belief frequency, presence of conflicting beliefs and the content of the beliefs indicating relevance.
RESULTS: Nine TDF domains were identified as relevant to primary care clinicians: Knowledge, Environmental context and resources, Memory, Decision and attention processes, Beliefs about capabilities, Skills, Emotions, Reinforcement and Behavioural regulation. Relationships across domains were identified, including how primary care clinician confidence and working in a highly pressurized environment can affect behaviour.
CONCLUSION: We have identified key barriers and enablers to timely recognition and referral behaviour. These beliefs identify targets for theory-driven behaviour change interventions to reduce delays in CLTI pathways.
Retrospective data from the control group comprised of 105 patients directly preceding the intervention group who are underwent stem cell transplant or CAR-T therapy. Such control group information will be obtained via a research data request. Only de-identified data will be obtained for these subjects.
In support of NIH goals to improve people's health and support a healthy lifestyle, we will conduct a randomized trial to evaluate an age-targeted web-based intervention designed to improve the diet of a young adults (ages 21-30) as they navigate a new life stage of greater independence. The goal of our study is to increase daily intake of fruits and vegetables(FV) for young adults born in or after 1980, known as "Generation Y" (GenY), using relevant features that appeal to this group. This five-year project has two phases. In the first phase, we will use focus groups to confirm planned, key intervention elements that target needs and preferences of GenY and will build engagement in the intervention, as we revise our tested, effective Internet- based intervention (Making Effective Nutrition Choices or MENU, U19-CA079689). The MENU study was designed to support an increase in FV intake, and relied solely on e-media (internet and email). In the proposed study we will revise the MENU curriculum, applying age-targeted and theory-based methods to improve intervention engagement and effectiveness for GenY dietary behavior change. The intervention will use three psychosocial features which have been subject to empirical examination by age group: Social Cognitive Theory, Self-Determination Theory (SDT), with special attention to Social Marketing Theory(SMT), which emphasizes understanding the total environment to better shape health communications.

In developing our program, we will apply knowledge about GenY from developmental psychology,guided by our consultants and formative research on individual, environmental and societal factors collected in our preliminary studies and Phase I GenY focus groups. Focus group members will evaluate our validated MENU intervention, as well as our revised age-targeted, interactive "MENU GenY" intervention prior to launch. In the second phase, we will evaluate the efficacy of the MENU GenY interventions, including the added value of the self-initiated, personalized e-coaching support by email, as a supplement to the tailored online intervention. Specifically, using a sample of 1624 adults,ages 21 - 30 and from two geographically distinct regions (urban Detroit and rural Pennsylvania), and employing a randomized, three arm design, the primary aims of Phase II are to 1) determine if an agetargeted,tailored web-based intervention is more efficacious in improving primary outcome of daily intake of FV compared to an untailored intervention arm with no age targeting (control arm); 2) determine if a tailored webbased intervention with age targeting and personalized e-coaching support is more efficacious than the control; and 3) determine if the tailored web-based intervention with age targeting and e-counseling is more efficacious than a tailored web-based intervention with age targeting alone.
Ossification of the posterior longitudinal ligament of the cervical spine (C-OPLL) is a degenerative disorder that leads to the narrowing of the spinal canal and compression of both the spinal cord and nerve roots. This condition is more prevalent in East Asian populations, with marked regional variations in incidence. Symptoms include neck pain, restricted movement, limb numbness, and motor impairment. In severe cases, surgery may be required.Surgical strategies for C-OPLL can be divided into anterior and posterior approaches, each offering distinct advantages and limitations. Anterior approaches, such as anterior cervical corpectomy and fusion (ACCF), anterior cervical discectomy and fusion (ACDF), anterior floating method and vertebral body sliding osteotomy (VBSO), provide the benefit of direct decompression but are technically demanding and carry a higher risk of complications. In contrast, posterior approaches, including laminectomy (with or without instrumented fusion) and laminoplasty (LAMP), offer indirect decompression but may increase the risk of cervical kyphosis. In recent years, innovative techniques like anterior cervical ossified posterior longitudinal ligament en bloc resection (ACOE), anterior controllable antedisplacement and fusion (ACAF), and minimally invasive endoscopic spine surgery have been developed to reduce complications and enhance surgical outcomes.Selecting the appropriate surgical technique requires a thorough assessment of factors such as the severity of the lesion, cervical alignment, and the surgeon's experience. This narrative review examines the differences between these surgical options, discusses their respective advantages and disadvantages, and provides updated insights and recommendations.
PROBLEM TO BE SOLVED: To provide a novel EGFR binding agent capable of being used for diagnostic, in vitro or in vivo imaging, as well as therapeutic application.SOLUTION: Epidermal growth factor receptor (EGFR) binding polypeptide contains an epidermal growth factor receptor binding motif, EBM, composed of a specific amino acid sequence and binds to EGFR such that the KD value of the interaction is at most 10 μM. Polynucleotide encodes the polypeptide. A producing method of the polypeptide comprises the step of expressing the polynucleotide. A combination of the EGFR binding polypeptide and a detectable agent, and a combination of the EGFR binding polypeptide and a therapeutic agent are also provided. A detection method of the EGFR comprises the steps of: contacting a sample with the EGFR binding polypeptide or the combination; and detecting binding of the polypeptide or the combination to indicate the presence of the EGFR in the sample. Further, a method of treatment of an EGFR-related condition in a mammalian subject or in material derived from a mammalian subject is provided.
Villages classified as high incidence, low probability of elimination (P. falciparum cumulative incidence \>84 cases/1000/year, in spite of \>1 year of functioning malaria post) will be eligible to be included in group 1. Villages in this group will be addressed by MSAT waves of 10-15 villages. Interventions will consist of 1 Ultrasensitive Rapid Diagnostic Test (URDT) and antimalarials drugs.
The present disclosure relates to isolating one or more cannabinoids from an input mixture. There is disclosed an apparatus that comprises a volatizing unit, a fractional distillation unit, and a condensing unit. The volatizing unit receives and volatilizes the input mixture to provide a cannabinoid-containing vapor stream and a residue. The fractional distillation unit comprises a plenum for receiving the cannabinoid-containing vapor stream and separates a first cannabinoid from at least a second cannabinoid. The condensing unit is configured to receive a portion of the cannabinoid-containing vapor stream comprising the first cannabinoid from the plenum and to form a condensed first cannabinoid output stream and a recirculate stream. There are also disclosed methods for isolating one or more cannabinoids employing a recirculate stream.
BACKGROUND: Balloon pulmonary angioplasty improves the hemodynamics of patients with inoperable chronic thromboembolic pulmonary hypertension; however, the clinical impact of recurrent pulmonary hypertension after balloon pulmonary angioplasty remains unclear.
METHODS: We retrospectively reviewed 262 consecutive patients with chronic thromboembolic pulmonary hypertension who underwent balloon pulmonary angioplasty between July 2009 and December 2020; 158 (65 ± 12 years; males, 20%; median follow-up period, 45 [26, 66] months) with follow-up right heart catheterization and no residual pulmonary hypertension were included. Recurrent pulmonary hypertension was defined as mean pulmonary arterial pressure <25 mm Hg at the first evaluation after balloon pulmonary angioplasty and ≥25 mm Hg at follow-up evaluation requiring additional treatment with balloon pulmonary angioplasty or pulmonary vasodilators.
RESULTS: Recurrent pulmonary hypertension was observed in 11 patients; the state occupation probability of recurrence at 5 years was 9.0% (95% confidence interval: 5.0%-18.9%). Only 1 case (0.6%) of recurrent pulmonary hypertension showed vascular restenosis and reocclusion of previously treated lesions, with more significant hemodynamic and exercise capacity deterioration than the other cases. Additional treatments for recurrent pulmonary hypertension (balloon pulmonary angioplasty in 9 patients, pulmonary vasodilators in 4 patients) improved the mean pulmonary arterial pressure from 27 [26, 29] to 22 [19, 23] mm Hg (p < 0.01). Recurrence had a low probability of transitioning to death in an illness-death model. No specific risk factors for recurrent pulmonary hypertension were identified.
CONCLUSIONS: Symptomatic recurrent pulmonary hypertension due to vascular restenosis or reocclusion after balloon pulmonary angioplasty was extremely rare. Most cases of recurrent pulmonary hypertension were mild, did not worsen clinically, and had favorable prognoses.
Only a small percentage of our population (e.g., the rich and power) can afford dedicated personal human doctors hence live healthier and longer. Healthcare inequality is a fundamental challenge to our society. Social and policy solutions such as ObamaCare are difficult to implement. Our invention intends to provide a technology solution by getting everyone a data-driven artificial intelligence (AI) personal doctor (AIPD), i.e. the first trainable Robot Doctor. We invent new methods and systems to create and train the artificial brains (AB) of the first trainable robot doctor named AIPD on NLP and deep learning technologies. The AB of AIPD can be pre-trained with validated health literature from authorities and can be continuously trained with NLP and deep learning algorithms by the growing literature and user contacts. The first robot doctor's response by its AB can be validated by a human doctor or can be cross-validated from another AIPD robot doctor with a different trainable artificial brain.
Adult cigarette smokers with a SMI diagnosis randomized to the EC arm will receive NRT including nicotine patches and lozenges. Participants will also receive telehealth motivational counseling during the intervention period of 8 weeks.
A composition for use as a dental impression material including a polymerizable resin consisting of oligomers or polymers functionalized with groups curable by ring opening metathesis polymerization. These oligomers or polymers are end-capped and/or tethered with said functional groups. The composition also includes a ruthenium carbene complex catalyst, whereby the catalyst initiates ring-opening metathesis polymerization of the composition. The invention includes a paste/paste system in which a base paste includes the polymerizable oligomer or polymer and an inorganic dental filler system and in which a catalyst paste includes the catalyst dissolved in an inert solvent and an inorganic dental filler system. The oligomer or polymer may be, for example, one or a combination of a telechelic polydimethylsiloxane end-capped with norbornenyl groups, a polydimethylsiloxane tethered and end-capped with norbornenyl groups, a tri-functional polydimethylsiloxane end-capped with norbornenyl grou ps, or a quadri-functional polydimethylsiloxane end-capped with norbornenyl groups. The catalyst may be, for example, a ruthenium carbene complex with a ligand having a basicity higher than tricyclohexylphosphine. The composition of the present invention exhibits reduced sensitivity to sulfur impurities.
Subjects will first receive oral lollipop with oxytocin (24IU). After a washout period of 2 weeks, they will then receive oral lollipop with placebo (identical ingredients, except the active agent).
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: there are described compounds of formula I: , their pharmaceutically acceptable salts where R1-R7, Y and n are specified in the patent claim. The compounds exhibit inhibitory action in the relation to aurora A tyrosine kinase. There is also described a drug of the compound of formula (I). The drug can be used for control or prevention of diseases, such as cancer. ^ EFFECT: preparation of new phthalazinone derivatives which can be used for control or prevention of diseases, such as cancer. ^ 17 cl, 2 tbl, 41 ex
Chronic kidney disease (CKD) is a growing health concern with a complex etiological landscape. Among the numerous factors implicated, vitamin D binding protein (VDBP) has emerged as a focal point of scientific studies because of its critical role in vitamin D metabolism and immune modulation. The relationship between VDBP and CKD reveals a complex web of molecular and biochemical details that have great potential for improving diagnostic understanding and treatment strategies for CKD. This review summarizes the multifaceted roles of VDBP, including its molecular dynamics, interactions with vitamin D, and subsequent implications for kidney function. The main focus of the discussion is how VDBP affects bone mineral homeostasis, highlighted by the dysregulation of calcium and phosphorus metabolism, which is a part of the pathophysiology of CKD. The discussion also touches on the immunomodulatory scope of VDBP and how it may reduce the chronic inflammatory environment that accompanies CKD. The diagnostic potential of VDBP as a biomarker for CKD has been rigorously examined, highlighting its capacity to improve early detection and prognostic assessment. Modification of VDBP activity has the potential to slow the course of CKD and improve patient outcomes. Furthermore, a detailed examination of the genetic polymorphisms of VDBP and their implications for CKD susceptibility and treatment responsiveness provides a perspective for personalized medical methods. Prospects for the future depend on the expansion of studies that try to understand the molecular mechanisms underlying the VDBP-CKD interaction, in addition to clinical trials that evaluate the effectiveness of VDBP-focused treatment approaches.
BACKGROUND/OBJECTIVE: Intracranial epidermoid tumors (ETs) are rare, benign lesions that present significant challenges in neurosurgical management due to their propensity to encase vital neurovascular structures. We aimed to evaluate the impact of clinical, demographic, and tumor-specific factors on surgical decisions (gross total resection [GTR] vs. subtotal resection [STR]) and outcomes and identify patient clusters with distinct profiles and outcomes post-resection.
METHODS: We retrospectively analyzed 72 patients with ET treated from 1998 to 2022, employing multivariable logistic regression for GTR versus STR predictors and Kaplan-Meier curves for progression-free survival (PFS). K-prototype clustering classified patients based on clinical data.
RESULTS: The mean age of our cohort was 39.8 ± 20.1 years. About 13.9% of patients had a recurrence, with a median PFS of 108 months (interquartile range: 57 -206). Seizures significantly predicted GTR (P < 0.05), whereas adherence to critical structures reduced GTR likelihood (P < 0.05). Initial surgeries more often achieved GTR, correlating with longer PFS (P < 0.0001) and reduced recurrence (P < 0.01) versus re-operations. Cluster analysis identified three distinct groups, with the initial GTR cluster showing superior PFS and the lowest recurrence (P < 0.0001 and P < 0.01, respectively). Statistically significant predictors of PFS included age and preoperative seizure presence, with older age favoring longer PFS (P < 0.01) and seizures associated with reduced PFS (P < 0.01). In addition, patients with previous surgeries showed a trend toward shorter PFS (P < 0.05).
CONCLUSIONS: This study emphasizes the importance of tailored surgical strategies in managing intracranial ETs, advocating for GTR to optimize long-term outcomes where possible. Future prospective studies are essential to further refine treatment approaches, enhancing survival for ET patients.
Primary implantation with HMIOL through Month 1 visit, followed by study exit. 1 site followed up to Month 12.
Participants in this cohort will complete a questionnaire about their use of hyperglycemia medications. Participants from Cohort 2a will take part in this group.
OBJECTIVES: The purposes of this study were to examine indications, radiographic outcomes, and clinical complications for primary arthrodesis of the great toe interphalangeal (IP) joint in young patients.
BACKGROUND: Hallux valgus interphalangeus deformity of the great toe is uncommon in the pediatric population and often requires fusion of the IP joint.
METHODS: A retrospective review of patients, ages 8 to 19 years, who underwent operative fusion of the great toe IP joint, and had >1 year radiographic follow-up was performed. Medical records and radiographs were reviewed to determine indications for surgery, concomitant procedures, success of fusion, complications, and need for revision procedures or elective hardware removal. Differences between pre and postradiographic outcomes for the hallux valgus angle, IP angle, and intermetatarsal angle were analyzed.
RESULTS: Twenty-seven patients (31 feet) were included in the analyses. The average age at fusion surgery was 14.9 years (SD ± 2.3) with a mean follow-up visit of 35.2 months. The most common indications for fusion of the great toe IP joint were pain and deformity. Kirschner wire fixation was utilized in 7 cases, with the remaining 24 cases fixed with a single retrograde cannulated screw. Fifty-five concomitant toe and foot procedures were performed in 21 feet (68%) to address additional foot and toe deformity. Successful fusion occurred in 30 of 31 toes after the primary fusion. Patient satisfaction with the toe position and diminished pain were high (94.1%). Significant improvement was noted in the measure of the IP angle ( P < 0.001), with minimal clinical change in the hallux valgus angle ( P = 0.24) or the intermetatarsal angle ( P = 0.03).
CONCLUSIONS: Hallux valgus interphalangeus of the great toe was successfully managed with the fusion of the IP joint. Single screw fixation or the use of Kirschner wires led to similar outcomes. Hardware-related issues with the use of screws were the most common adverse outcome. Patients should be made aware of the possible need for hardware removal after fusion utilizing screw fixation.
LEVEL OF EVIDENCE: Level IV-a retrospective case series.
FIELD: medicine, immunology, phytotherapy. SUBSTANCE: invention relates to development of medicinal preparations of the plant origin. Agent has haw-thorn fruits, Leuzea carthamoides roots and snowdon rose roots taken in the definite ratio. Except for, deviating peony, erianthous milk vetch and bean valves can be added to the proposed species. Agent can be made as 20-70% spirituous tincture.. Agent prevents decrease of T-lymphocytes level at climate-geographic stress, sporting stress, it does not show toxic and allergic effect. Agent is excreted from body rapidly. EFFECT: enhanced effectiveness of agent, valuable properties. 3 cl, 1 tbl
The dose of investigational drug (study treatment), as well as all other components of the overall nutritional regimen is solely at the discretion of the Investigator. It is assumed the Investigator will use sound medical judgement, follow institutional standards of care regarding the nutrition provided to each patient, and review applicable prescribing information indicating the maximum and recommended dose of Omegaven of 1 g/kg/day infused intravenously over 8 to 24 hours as long as the infusion rate does not exceed 1.5 mL/kg/hour.
A biologically pure culture of Bacillus subtilis strain AQ713, NRRL Accession No. B-21661 is disclosed. The supernatant of this strain exhibits antifungal and antibacterial activity against corn rootworm.  A metabolite thereof which is solvent extractable and has a molecular weight of less than 10,000 daltons also exhibits activity against corn rootworm. A composition comprising a chemical fungicide (or a biological or chemical pesticide) and the whole broth culture of Bacillus subtilis strain AQ713 is also disclosed. The Bacillus subtilis strain AQ713 is useful for protecting or treating plants from fungal and bacterial infections and corn rootworm infestations. An agrastatin and a surfactin lipopeptide can be isolated for the strain AQ713 A combination of an A-type iturin, a plipastatin, a surfactin and an agrastatin is disclosed